EGFR (Epidermal Growth Factor Receptor) mutations cause oncogenic signaling in non-small cell lung cancer (NSCLC) and glioblastoma, hence increasing tumor growth and resistance against EGFR tyrosine kinase inhibitors (TKIs). The gene discussed is EGFR; the disease is glioblastoma.